Endocrine disruptor mediated activation of PXR causes dyslipidemia

内分泌干​​扰物介导的 PXR 激活导致血脂异常

基本信息

  • 批准号:
    8613600
  • 负责人:
  • 金额:
    $ 33.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-09-26 至 2018-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The goal of this project is to investigate a novel mechanism linking exposure to endocrine disrupting chemicals (EDCs) with dyslipidemia and cardiovascular disease. The pregnane X receptor (PXR) is a nuclear receptor activated by numerous drugs, xenobiotic and dietary chemicals. Many EDCs activate PXR, including organochlorine and organophosphate pesticides, alkylphenols, phthalates, polychlorinated biphenyls, bisphenol A and its analogs. However, the role of PXR in mediating the pathophysiological effects of EDCs in humans and animals remains elusive. Mounting evidence implicates EDC exposure in the development of chronic human diseases but the contribution of these EDCs to the etiology of cardiovascular disease (CVD), obesity, and diabetes is poorly understood. We have recently revealed the pro-atherogenic effects of PXR in animal models and demonstrated that chronic PXR activation induces hyperlipidemia in wild-type mice and increases atherosclerosis in atherosclerosis-prone apolipoprotein E deficient (ApoE-/-) mice. Our central hypothesis is that EDCs which activate PXR will lead to hyperlipidemia and accelerated atherosclerosis in mice, thereby increasing the risk of CVD in exposed individuals. We propose the following specific aims to test this hypothesis: 1) What are the molecular mechanisms through which intestinal PXR activation induces hyperlipidemia? 2) How does exposure to FDA-approved phthalate substitute plasticizers elevate plasma lipid levels in mice? 3) Is EDC-mediated PXR activation necessary and sufficient to increase atherosclerosis development in ApoE-/- mice? Our research will establish the role of PXR in linking exposure to EDCs with hyperlipidemia and CVD, and will provide novel mechanistic links explaining how EDC exposure causes atherogenic effects. These studies are broadly translational and will provide strong evidence to inform future risk assessment for EDCs.
描述(由申请人提供):本项目的目标是研究将内分泌干扰物(EDCs)暴露与血脂异常和心血管疾病联系起来的新机制。PXR是一种由多种药物、外源性化学物质和膳食化学物质激活的核受体。许多内分泌干扰物都会激活PXR,包括有机氯和有机磷农药、烷基酚、邻苯二甲酸酯、多氯联苯、双酚A及其类似物。然而,PXR在人类和动物中介导内分泌干扰物的病理生理学作用的作用仍然是难以捉摸的。越来越多的证据表明EDC暴露与人类慢性疾病的发展有关,但这些EDC对心血管疾病(CVD)、肥胖和糖尿病的病因学的贡献却知之甚少。我们最近在动物模型中揭示了PXR的促动脉粥样硬化作用,并证明了慢性PXR激活诱导野生型小鼠高脂血症,并增加动脉粥样硬化倾向载脂蛋白E缺陷(ApoE-/-)小鼠的动脉粥样硬化。我们的中心假设是,激活PXR的EDCs会导致小鼠高脂血症和加速动脉粥样硬化,从而增加暴露个体的CVD风险。我们提出以下具体目标来验证这一假设:1)肠道PXR激活诱导高脂血症的分子机制是什么?2)暴露于FDA批准的邻苯二甲酸酯替代增塑剂如何升高小鼠的血脂水平?3)EDC介导的PXR激活是否是增加ApoE-/-小鼠动脉粥样硬化发展的必要和充分条件?我们的研究将确定PXR在将暴露于EDC与高脂血症和CVD联系起来中的作用,并将提供解释EDC暴露如何导致动脉粥样硬化效应的新机制联系。这些研究具有广泛的转化性,将为未来的内分泌干扰物风险评估提供强有力的证据。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Changcheng Zhou其他文献

Changcheng Zhou的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Changcheng Zhou', 18)}}的其他基金

Role of PXR in EDC-induced cardiovascular disease
PXR 在 EDC 诱发的心血管疾病中的作用
  • 批准号:
    10640665
  • 财政年份:
    2023
  • 资助金额:
    $ 33.25万
  • 项目类别:
Core D - Energy Balance and Body Composition Core
核心 D - 能量平衡和身体成分核心
  • 批准号:
    10225373
  • 财政年份:
    2018
  • 资助金额:
    $ 33.25万
  • 项目类别:
Core D - Energy Balance and Body Composition Core
核心 D - 能量平衡和身体成分核心
  • 批准号:
    10458566
  • 财政年份:
    2018
  • 资助金额:
    $ 33.25万
  • 项目类别:
Core D - Energy Balance and Body Composition Core
核心 D - 能量平衡和身体成分核心
  • 批准号:
    9982358
  • 财政年份:
    2018
  • 资助金额:
    $ 33.25万
  • 项目类别:
Role of IKKβ in obesity and atherosclerosis
IKKβ 在肥胖和动脉粥样硬化中的作用
  • 批准号:
    10008480
  • 财政年份:
    2016
  • 资助金额:
    $ 33.25万
  • 项目类别:
A novel mechanism for ART-associated dyslipidemia and atherosclerosis
ART 相关血脂异常和动脉粥样硬化的新机制
  • 批准号:
    9109680
  • 财政年份:
    2015
  • 资助金额:
    $ 33.25万
  • 项目类别:
A novel mechanism for ART-associated dyslipidemia and atherosclerosis
ART 相关血脂异常和动脉粥样硬化的新机制
  • 批准号:
    9273599
  • 财政年份:
    2015
  • 资助金额:
    $ 33.25万
  • 项目类别:
Mechanisms of atherogenic effects of bisphenol A
双酚A致动脉粥样硬化作用的机制
  • 批准号:
    8638093
  • 财政年份:
    2014
  • 资助金额:
    $ 33.25万
  • 项目类别:
Mechanisms of atherogenic effects of bisphenol A
双酚A致动脉粥样硬化作用的机制
  • 批准号:
    8828205
  • 财政年份:
    2014
  • 资助金额:
    $ 33.25万
  • 项目类别:
Endocrine disruptor mediated activation of PXR causes dyslipidemia
内分泌干​​扰物介导的 PXR 激活导致血脂异常
  • 批准号:
    9308696
  • 财政年份:
    2013
  • 资助金额:
    $ 33.25万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 33.25万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 33.25万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 33.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 33.25万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 33.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 33.25万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 33.25万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 33.25万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 33.25万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 33.25万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了